Advanced

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Hoglund, Martin ; Sandin, Fredrik ; Hellstrom, Karin ; Bjoreman, Mats ; Bjorkholm, Magnus ; Brune, Mats ; Dreimane, Arta ; Ekblom, Marja LU ; Lehmann, Soren and Ljungman, Per , et al. (2013) In Blood 122(7). p.1284-1292
Abstract
Clinical management guidelines on malignant disorders are generally based on data from clinical trials with selected patient cohorts. In Sweden, more than 95% of all patients diagnosed with chronic myeloid leukemia (CML) are reported to the national CML registry, providing unique possibilities to compile population-based information. This report is based on registry data from 2002 to 2010, when a total of 779 patients (425 men, 354 women; median age, 60 years) were diagnosed with CML (93% chronic, 5% accelerated, and 2% blastic phase) corresponding to an annual incidence of 0.9/100 000. In 2002, approximately half of the patients received a tyrosine kinase inhibitor as initial therapy, a proportion that increased to 94% for younger (<70... (More)
Clinical management guidelines on malignant disorders are generally based on data from clinical trials with selected patient cohorts. In Sweden, more than 95% of all patients diagnosed with chronic myeloid leukemia (CML) are reported to the national CML registry, providing unique possibilities to compile population-based information. This report is based on registry data from 2002 to 2010, when a total of 779 patients (425 men, 354 women; median age, 60 years) were diagnosed with CML (93% chronic, 5% accelerated, and 2% blastic phase) corresponding to an annual incidence of 0.9/100 000. In 2002, approximately half of the patients received a tyrosine kinase inhibitor as initial therapy, a proportion that increased to 94% for younger (<70 years) and 79% for older (>80 years) patients during 2007-2009. With a median follow-up of 61 months, the relative survival at 5 years was close to 1.0 for patients younger than 60 years and 0.9 for those aged 60 to 80 years, but only 0.6 for those older than 80 years. At 12 months, 3% had progressed to accelerated or blastic phase. Sokal, but not European Treatment and Outcome Study, high-risk scores were significantly linked to inferior overall and relative survival. Patients living in university vs nonuniversity catchment areas more often received tyrosine kinase inhibitors up front but showed comparable survival. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Blood
volume
122
issue
7
pages
1284 - 1292
publisher
American Society of Hematology
external identifiers
  • wos:000323392900028
  • scopus:84886776435
  • pmid:23843494
ISSN
1528-0020
DOI
10.1182/blood-2013-04-495598
language
English
LU publication?
yes
id
8a93f11b-8651-4486-b1be-f73f21bc1467 (old id 4063457)
date added to LUP
2016-04-01 11:07:42
date last changed
2020-09-30 01:52:53
@article{8a93f11b-8651-4486-b1be-f73f21bc1467,
  abstract     = {Clinical management guidelines on malignant disorders are generally based on data from clinical trials with selected patient cohorts. In Sweden, more than 95% of all patients diagnosed with chronic myeloid leukemia (CML) are reported to the national CML registry, providing unique possibilities to compile population-based information. This report is based on registry data from 2002 to 2010, when a total of 779 patients (425 men, 354 women; median age, 60 years) were diagnosed with CML (93% chronic, 5% accelerated, and 2% blastic phase) corresponding to an annual incidence of 0.9/100 000. In 2002, approximately half of the patients received a tyrosine kinase inhibitor as initial therapy, a proportion that increased to 94% for younger (&lt;70 years) and 79% for older (&gt;80 years) patients during 2007-2009. With a median follow-up of 61 months, the relative survival at 5 years was close to 1.0 for patients younger than 60 years and 0.9 for those aged 60 to 80 years, but only 0.6 for those older than 80 years. At 12 months, 3% had progressed to accelerated or blastic phase. Sokal, but not European Treatment and Outcome Study, high-risk scores were significantly linked to inferior overall and relative survival. Patients living in university vs nonuniversity catchment areas more often received tyrosine kinase inhibitors up front but showed comparable survival.},
  author       = {Hoglund, Martin and Sandin, Fredrik and Hellstrom, Karin and Bjoreman, Mats and Bjorkholm, Magnus and Brune, Mats and Dreimane, Arta and Ekblom, Marja and Lehmann, Soren and Ljungman, Per and Malm, Claes and Markevarn, Berit and Myhr-Eriksson, Kristina and Ohm, Lotta and Olsson-Stromberg, Ulla and Sjalander, Anders and Wadenvik, Hans and Simonsson, Bengt and Stenke, Leif and Richter, Johan},
  issn         = {1528-0020},
  language     = {eng},
  number       = {7},
  pages        = {1284--1292},
  publisher    = {American Society of Hematology},
  series       = {Blood},
  title        = {Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry},
  url          = {http://dx.doi.org/10.1182/blood-2013-04-495598},
  doi          = {10.1182/blood-2013-04-495598},
  volume       = {122},
  year         = {2013},
}